Archive for the ‘investor relations’ Category

Communications in a Fantex World: Implications for George Clooney’s Stock

Tuesday, October 22nd, 2013

We are big fans of VC Lisa Suennen and her blog Venture Valkyrie. In a recent post, A Star is Bought, Sold and Shorted, she enlightens us about Fantex, a start-up that plans to create a stock market out of famous people. Lisa muses about the potential anxiety of owning shares of George Clooney stock, but the cachet of being able to tell her friends, “Oh George Clooney, I own him,” would be well worth it.

Lisa smartly anticipates that an entire new supporting economy would sprout. What a blast it’d be to be a stockbroker or a sell-side analyst! But what about the publicists? Oh my…just think if the PR people for the celebrity or pro athletes’ stock had to comply with SEC regulations! No more selective placements of juicy rumors with media outlets that may not qualify as fair disclosure. No PR person could write a press release fast enough, and the legal team would tear their hair out trying to define materiality – oh hell, they’d throw in the towel – it’s all material in Hollywood, the NFL, NBA and USCF, etc. Surely with more than 40 million followers, @LadyGaga can serve as an established channel for broadly disseminating material information.

Imagine the gyrations of a celebrity stock fueled by social media. Movie star gawkers sipping craft cocktails at Hollywood’s hottest nightspot won’t have their camera phones at the ready. Instead the eTrade app will be cued to buy or sell as they watch for Lindsay Lohan’s next move, then fire off a tweet or post a “like” to pump the stock.

Fantex could alter other forms of investor communications. The US and inTouch tabloids would be replaced on newsstands by annual reports, which would mean a huge come-back for all the design firms that adopted electronic annual reports and lean 10K wraps.

Imagine quarterly earnings reports. We get excited when 100 investors dial-in for a life sciences earnings call. Millions would tune-in to George Clooney’s report. Servers might crash. How the heck do you decide which investor gets to ask a question during the Q&A? Thomson would create an entirely new portfolio of products to cater to this market.

What comes to mind when you imagine this sort of “craz[y]…potentially lucrative and destructive idea,” per Lisa? How do you view this Fantex market? Kudos to them for a brilliant idea! Great fuel for thought. It’ll be fascinating to see if this plays out.

Show Me the Money. San Diego Life Science Investments are Hot, Hot, Hot!

Tuesday, October 8th, 2013

bigstock-Summer-piggy-bank-with-sunglas-36474748The CanaleComm team makes it a point to stay on top of life science and financing news and one way to do this is attending many of San Diego’s great events, especially those put on by BIOCOM and San Diego Venture Group (SDVG). CanaleComm’s president, Carin Canale-Theakston, sits on the board of both of these organizations and along with her team, shares a few nuggets they picked up last month:

The SDVG meeting, “Series A Financing,” took place September 19th. The meeting provided some good data to confirm that life sciences investments really are as hot as everyone has heard, and hopefully look to stay that way for some time. According to Renaissance Capital, 2013 has already had 176 IPOs – 34 of which are healthcare and biotechnology companies, the most in any sector. This already represents a 62 percent increase over the IPO activity in all of 2012. This news is especially exciting for San Diego, which has seen six life sciences companies go public since May: Ambit Biosciences Corp., Conatus Pharmaceuticals Inc., Receptos Inc. Sophiris Biosciences Inc., Evoke Pharma Inc., and Fate Therapeutics Inc.; all of which have seen their stock prices hold steady or soar. Biocept Laboratories has filed and is expected to start trading publicly soon.

Then the panel turned to talking about how a company can actually complete a Series A funding. Neil Senturia of Blackbird Ventures made the point that “your product has to solve a problem” in order to get funding. Venture capitalists look at thousands of deals every year so yours has to stand out. San Diego biotech has also seen some strong Series A deals this year. Two of our clients, Lumena Pharmaceuticals and eFFECTOR Therapeutics raised $23M and $45M, respectively in their Series A rounds announced earlier this year. That’s certainly not chump change!

The BIOCOM event held on September 25th further highlighted the vintage year for the San Diego biotech, focusing on some recent M&A action in addition to the hot IPO market. For example, in the second quarter of this year alone, over a billion dollars was pumped into two local biotechs by their new parents – $650M to acquire private Aragon Pharmaceuticals and $707M to acquire public Trius Therapeutics.

The panel had an interesting conversation on the decision to stay independent and build versus selling to a big biotech or pharma. Kleanthis Xanthopolous, CEO at Regulus, had a strong opinion that we shouldn’t be so quick to give in when pharma comes calling because San Diego needs to have more, big biotech with commercial infrastructure. Jeff Stein at Trius and Rich Heyman at Aragon evaluated all options and concluded their therapeutics were better served by big pharma who could more quickly and effectively get them to patients. Regardless of which camp you are in, one thing is for sure – Jeff and Rich certainly seemed to be more relaxed on the stage!

Thanks to SDVG and BIOCOM for putting on such great events – we always appreciate the discussions!

CanaleComm Executives Published Twice in BIOCOM Magazine

Monday, July 1st, 2013

Canale Executives Heidi and Carin featured in BIOCOM's LifeLines

Canale Communications had two thought leadership pieces published in the summer issue of LifeLines, BIOCOM’s magazine geared towards the Southern California life sciences community.

Carin Canale-Theakston published the cover story, “Paying it Forward – San Diego’s Biotech Guardian Angels.” In this piece she surmised that San Diego is actually on the upswing for venture capital investments in the life sciences. She concludes that San Diego’s biotech cluster is more well-known than many realize thanks to our early-stage innovation from the region’s great research institutes and universities. She also notes that angel investors are watching over the San Diego life science scene closely, and that local startups are in a great place to find funding here. Plus, San Diego has rich resources and a community that continually gives back to its own, so we are all fortunate to be here.

Once you have your company or are looking to take one off, it pays to have a message that clearly resonates. “How to Tell a Story That Sells,” was contributed by CanaleComm Account Director, Heidi Chokeir, Ph.D. Heidi noted that it is important to describe your business and its technology in a clear, concise and differentiating way. You don’t want to use scientific jargon or catch phrases that have become meaningless. Heidi also warns not to make outrageous claims – don’t say you’ve cured cancer if you have only cured it in mice. We all know that if it sounds too good to be true, it probably is. Investing in a company positioning statement, strong supporting messages and good communication tools will only enhance your company’s long-term value.

Read the full articles here.